# Kamal Ramzipoor

> Kamal Ramzipoor is the founder and chief technology officer of R3 Vascular and its former CEO. His career spans technical development, manufacturing, capital raising and executive leadership, including co-founding Amaranth Medical and collaborating with materials researchers in Singapore. R3 announced his transition to CTO alongside its $87 million Series B in May 2024.

- **Role:** Founder and Chief Technology Officer at R3 Vascular
- **Organizations:** R3 Vascular, Amaranth Medical, Boston Scientific, Micrus Endovascular, Acuson, Progressive Angioplasty Systems, Guidant, Crystalline Medical
- **Education:** Undergraduate degree; subject unspecified in the available biographical listing, Detroit Institute of Technology
- **Known for:** Founder and CTO of R3 Vascular; previously its CEO., Co-founded and led Amaranth Medical., R3 Vascular credits him with more than 150 issued or pending patent applications, authored or co-authored; this is a combined company-reported figure, not a count of granted patents.

## Career timeline

- **—** — Held engineering and development roles at Guidant, Progressive Angioplasty Systems and Acuson; later served as CTO and vice president of R&D at Micrus Endovascular and a director at Boston Scientific.
- **2013** — Named general manager and chief technical officer of Amaranth Medical in its October $20 million Series B announcement.
- **2014** — Named CEO of Amaranth Medical in its January announcement of an equity investment from Boston Scientific.
- **2015** — A Singapore government speech highlighted his Amaranth collaboration with NTU professors Freddy Boey and Subbu Venkatraman.
- **2020** — R3 Vascular announced his appointment as CEO alongside a $17.8 million Series A, including $2.8 million in converted notes.
- **2024** — R3 announced an $87 million Series B and his transition from CEO to CTO on May 9.
- **2025** — A patent application naming Ramzipoor and Richard J. Saunders as inventors was published on January 23 (US20250025609A1).

## Achievements

- Founder and CTO of R3 Vascular; previously its CEO.
- Co-founded and led Amaranth Medical.
- R3 Vascular credits him with more than 150 issued or pending patent applications, authored or co-authored; this is a combined company-reported figure, not a count of granted patents.
- Collaborated with NTU professors Freddy Boey and Subbu Venkatraman in the work from which Amaranth emerged.

## Latest updates

- **2026-09** — R3 Vascular appointed Lisa Wipperman Heine to its board on September 21; this is an organizational update, not a new appointment for Ramzipoor.
- **2026-08** — R3 Vascular appointed Robert Spanos VP of Global Market Development and Katie Segreto VP of Finance and Corporate Controller on August 24.
- **2025-01** — US20250025609A1 was published, naming Ramzipoor and Richard J. Saunders as inventors and Razmodics LLC as applicant.

## Links

- LinkedIn: https://www.linkedin.com/in/kamal-ramzipoor-71754b177

---

Profile page: https://yespress.io/kamal-ramzipoor
Published by YesPress — https://yespress.io
Last updated: 2026-10-25